Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 106

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 106
---
 the voting or disposition of any outstanding securities of the Company or any 
 Subsidiary of the Company.                                                                                                                                                                                                                               |

| (d) | Except as set forth in Schedule 2(d) to the Disclosure Letter, no holder of securities issued by the Company or                                                          
 any Subsidiary of the Company has any right to compel the Company to register or otherwise qualify securities for public sale in Canada, the United States or elsewhere. |

| (e) | The rights, privileges, restrictions and conditions attached to the Common Shares of the Company are as set out 
 in the articles of incorporation of the Company together with any amendments thereto or replacements thereof.   |

| (f) | Except as set out in Schedule 2(f) to the Disclosure Letter, no Shareholder has any existing participation                                    
 right or pre-emptive right or right of first refusal in respect of the allotment and issuance of any unissued or other shares of the Company. |

| 3. | Authority |

The Company has the requisite power and authority to enter into this Agreement and to perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by the Company and is a valid and binding agreement of the Company enforceable against the Company by the Purchaser in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws affecting creditors’ rights generally and subject to the qualification that equitable remedies may only be granted in the discretion of a court of competent jurisdiction. No other corporate proceedings are necessary to authorize the execution, delivery and performance of this Agreement or the completion of the transactions contemplated hereby, other than the Required Shareholder Approval, the Interim Order and the Final Order.

| 4. | No Violation |

| (a) | The execution and delivery by the Company of this Agreement and the performance by it of its obligations under 
 this Agreement and the acquisition of Common Shares pursuant to the Arrangement will not:                      |

| (i) | result (with or without notice or the passage of time) in a material violation or breach of or constitute a                                                                                                             
 default under, require an Authorization to be obtained under or give rise to any third party right of termination, amendment, cancellation, acceleration, penalty or payment obligation or right of purchase or sale or 
 pre-emptive or participation right under, any provision of:                                                                                                                                                             |

| (A) | its or its Subsidiary’s Constating Documents; |

| (B) | the